2026 EPS consensus $4.51. Backs FY25 revenue view $1.100B-$1.115B, consensus $1.1B. “Looking ahead, for the full year, we remain committed to rebuilding long-term supply chain capacity in Clear Eyes and expect to close the Pillar5 transaction as planned. We are reaffirming our FY26 net sales outlook which anticipates eye care supply improvements in second half thanks to these long-term capacity efforts. For profitability, we are now expecting earnings per share at the higher end of our previous range as well as free cash flow of $245M or more, driven by our strong financial profile and share repurchases executed in the second quarter,” he continued.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBH:
- Prestige Consumer Healthcare Reports Q2 Fiscal 2026 Results
- Prestige Consumer reports Q2 adjusted EPS $1.07, consensus 97c
- Prestige Consumer Healthcare (PBH) Q2 Earnings Cheat Sheet
- Prestige Consumer price target lowered to $71 from $75 at Jefferies
- Prestige Consumer price target lowered to $72 from $82 at Oppenheimer